$ZVSA
ZyVersa Therapeutics, Inc. Stock $zvsa

$zvsa Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224045351 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$1.834M
YoY Change		-17.73%
% of Gross Profit
Research & Development		$436.0K
YoY Change		-35.3%
% of Gross Profit
Depreciation & Amortization		$1.730K
YoY Change		-178.64%
% of Gross Profit
Operating Expenses		$2.270M
YoY Change		-21.81%
Operating Profit		-$2.270M
YoY Change		-21.81%
Interest Expense		-$131.6K
YoY Change		62585.71%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income		-$2.401M
YoY Change		-17.28%
Income Tax
% Of Pretax Income
Net Earnings		-$2.401M
YoY Change		-17.27%
Net Earnings / Revenue
Basic Earnings Per Share		-$2.43
Diluted Earnings Per Share		-$2.43
COMMON SHARES
Basic Shares Outstanding	2.344M shares	1.029M shares
Diluted Shares Outstanding		988.4K shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$122.9K
YoY Change		-92.21%
Cash & Equivalents		$122.9K
Short-Term Investments
Other Short-Term Assets		$267.5K
YoY Change		-37.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets		$390.4K
YoY Change		-80.53%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$18.65M
YoY Change
Total Long-Term Assets		$19.03M
YoY Change		-38.3%
TOTAL ASSETS
Total Short-Term Assets		$390.4K
Total Long-Term Assets		$19.03M
Total Assets		$19.42M
YoY Change		-40.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$9.285M
YoY Change		4.35%
Accrued Expenses		$2.257M
YoY Change		-18.67%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$11.54M
YoY Change		-1.41%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities		$11.54M
Total Long-Term Liabilities		$0.00
Total Liabilities		$12.40M
YoY Change		-5.72%
SHAREHOLDERS EQUITY
Retained Earnings		-$111.2M
YoY Change		23.69%
Common Stock		$107.00
YoY Change		-97.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$7.168K
YoY Change		0.0%
Treasury Stock Shares
Shareholders Equity		$7.027M
YoY Change
Total Liabilities & Shareholders Equity		$19.42M
YoY Change		-40.87%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$2.401M
YoY Change		-17.27%
Depreciation, Depletion And Amortization		$1.730K
YoY Change		-178.64%
Cash From Operating Activities		-$644.4K
YoY Change		-30.97%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		647.8K
YoY Change		-71.71%
NET CHANGE
Cash From Operating Activities		-644.4K
Cash From Investing Activities
Cash From Financing Activities		647.8K
Net Change In Cash		3.440K
YoY Change		-99.75%
FREE CASH FLOW
Cash From Operating Activities		-$644.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41184
	dei	Entity Registrant Name EntityRegistrantName	ZYVERSA THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2685744
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2200 N. Commerce Parkway
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 208
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33326
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001859007
CY2023Q4	us-gaap	Cash Cash	3137674	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	215459	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3353133	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6933	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18647903	usd
CY2023Q4	ZVSA	Vendor Deposit Non Current VendorDepositNonCurrent	98476	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1074196	shares
CY2024Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2024Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1074203	shares
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	7	shares
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	436043	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1833578	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2228735	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	2269621	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2902678	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2902678	usd
CY2024Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-131635	usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-210	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2401256	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-485	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-2401256	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2902403	usd
CY2023Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	32373	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2401256	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2934776	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts		usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2023Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2023Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2024Q1	ZVSA	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants		usd
CY2024Q1	ZVSA	Round Up Share Adjustment Due To Reverse Split RoundUpShareAdjustmentDueToReverseSplit		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	ZVSA	Shares Issued As Consideration For Extension Of Lockup Period SharesIssuedAsConsiderationForExtensionOfLockupPeriod		usd
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits		usd
	ZVSA	Increase Decrease Deferred Offering Costs IncreaseDecreaseDeferredOfferingCosts		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	ZVSA	Redemption Of Series Preferred Stock RedemptionOfSeriesPreferredStock		usd
	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity		usd
	ZVSA	Proceeds From Pre Funded Warrant Exercises ProceedsFromPreFundedWarrantExercises		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	ZVSA	Payments Of Preferred Stock Issuance Costs PaymentsOfPreferredStockIssuanceCosts		usd
	ZVSA	Reclassification Of Formerly Redeemable Common Stock ReclassificationOfFormerlyRedeemableCommonStock		usd
	ZVSA	Warrant Modification Incremental Value WarrantModificationIncrementalValue		usd
CY2024Q3	ZVSA	Milestone Payment Liability MilestonePaymentLiability		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2024Q3	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Warrants Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsNonOptionsOutstandingIntrinsicValue		usd
CY2024Q3	ZVSA	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1		usd
	dei	Document Type DocumentType	10-Q
	dei	Entity Address City Or Town EntityAddressCityOrTown	Weston
	dei	City Area Code CityAreaCode	(754)
	dei	Local Phone Number LocalPhoneNumber	231-1688
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	ZVSA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.0001
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2344191	shares
CY2024Q3	us-gaap	Cash Cash	122921	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	267494	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	390415	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18647903	usd
CY2024Q3	ZVSA	Vendor Deposit Non Current VendorDepositNonCurrent	178476	usd
CY2024Q3	us-gaap	Deferred Costs DeferredCosts	207130	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7839	usd
CY2024Q3	us-gaap	Assets Assets	19423924	usd
CY2023Q4	us-gaap	Assets Assets	22114284	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9284631	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8431583	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2257372	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1754533	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8656	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11542003	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10194772	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	854621	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	844914	usd
CY2024Q3	us-gaap	Liabilities Liabilities	12396624	usd
CY2023Q4	us-gaap	Liabilities Liabilities	11039686	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	405212	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	402205	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	107	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	40	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	107	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	40	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	118245220	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	114300849	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111210860	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103219124	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	7	shares
CY2024Q3	us-gaap	Treasury Stock Value TreasuryStockValue	7168	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	7168	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	7027300	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	11074598	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19423924	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22114284	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	673943	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1658030	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2950462	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6192205	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9694097	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	69280171	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11895033	usd
	us-gaap	Operating Expenses OperatingExpenses	7850235	usd
	us-gaap	Operating Expenses OperatingExpenses	93819763	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2269621	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7850235	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-93819763	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-131794	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	555	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2902888	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7982029	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-93819208	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9707	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8859762	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7991736	usd
	us-gaap	Net Income Loss NetIncomeLoss	-84959446	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	7948209	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7991736	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-92907655	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.43
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.43
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-30.18
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-30.18
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.79
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1591.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1591.46
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	988378	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	988378	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97252	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97252	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	816293	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	816293	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58379	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58379	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	11074598	usd
CY2024Q1	ZVSA	Exercise Of Warrant Value ExerciseOfWarrantValue	2672500	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	79200	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	223573	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2826737	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	11223134	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	160664	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2763743	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	8620055	usd
CY2024Q3	ZVSA	Stock Issued During Period Value Warrant Inducement Offer Exercise Proceeds StockIssuedDuringPeriodValueWarrantInducementOfferExerciseProceeds	400924	usd
CY2024Q3	ZVSA	Adjustments To Additional Paid In Capital Warrant Modification AdjustmentsToAdditionalPaidInCapitalWarrantModification	246912	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	160665	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-2401256	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	7027300	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	99662997	usd
CY2023Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	331331	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	395200	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-34674	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	287461	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3543950	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	97098365	usd
CY2023Q2	ZVSA	Registered Offering Of Common Stock Value RegisteredOfferingOfCommonStockValue	9831019	usd
CY2023Q2	ZVSA	Preferred Stock Redeemed Or Called During Period Value PreferredStockRedeemedOrCalledDuringPeriodValue	-10080001	usd
CY2023Q2	ZVSA	Shares Issued As Consideration For Extension Of Lockup Period Value SharesIssuedAsConsiderationForExtensionOfLockupPeriodValue	1156778	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	210000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	365742	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	-7168	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-78513093	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	20061642	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	20061642	usd
CY2023Q3	ZVSA	Registered Offering Of Common Stock Value RegisteredOfferingOfCommonStockValue	1575938	usd
CY2023Q3	ZVSA	Adjustments To Additional Paid In Capital Warrant Modification AdjustmentsToAdditionalPaidInCapitalWarrantModification	181891	usd
CY2023Q3	ZVSA	Preferred Stock Redeemed Or Called During Period Value PreferredStockRedeemedOrCalledDuringPeriodValue	-215048	usd
CY2023Q3	ZVSA	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants	947	usd
CY2023Q3	ZVSA	Stock Issued During Period Value Warrant Inducement Offer Exercise Proceeds StockIssuedDuringPeriodValueWarrantInducementOfferExerciseProceeds	757647	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	243045	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2902403	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	19703659	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	19703659	usd
CY2023Q2	ZVSA	Gross Proceeds From Issuance Initial Public Offering GrossProceedsFromIssuanceInitialPublicOffering	11015500	usd
CY2023Q2	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1184481	usd
CY2023Q3	ZVSA	Gross Proceeds From Issuance Initial Public Offering GrossProceedsFromIssuanceInitialPublicOffering	2099053	usd
CY2023Q3	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	523115	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7991736	usd
	us-gaap	Net Income Loss NetIncomeLoss	-84959446	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	69280171	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11895033	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	544902	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	896248	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	79200	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	605200	usd
	ZVSA	Shares Issued As Consideration For Extension Of Lockup Period SharesIssuedAsConsiderationForExtensionOfLockupPeriod	1156778	usd
	us-gaap	Depreciation Depreciation	6933	usd
	us-gaap	Depreciation Depreciation	7800	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	7839	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	67293	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	9707	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-8883001	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	52035	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	201172	usd
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	46659	usd
	ZVSA	Increase Decrease In Vendor Deposits IncreaseDecreaseInVendorDeposits	80000	usd
	ZVSA	Increase Decrease In Vendor Deposits IncreaseDecreaseInVendorDeposits	-235000	usd
	ZVSA	Increase Decrease Deferred Offering Costs IncreaseDecreaseDeferredOfferingCosts	30260	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	676178	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2871889	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-8656	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-74407	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	502839	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1122488	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6335089	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5933467	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	13114555	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	180142	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1763584	usd
	ZVSA	Redemption Of Series Preferred Stock RedemptionOfSeriesPreferredStock	10695610	usd
	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	7168	usd
	ZVSA	Proceeds From Pre Funded Warrant Exercises ProceedsFromPreFundedWarrantExercises	947	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2672500	usd
	ZVSA	Warrant Inducement Offer Exercise Proceeds WarrantInducementOfferExerciseProceeds	827978	usd
	ZVSA	Warrant Inducement Offer Exercise Proceeds WarrantInducementOfferExerciseProceeds	966349	usd
	ZVSA	Payments Of Preferred Stock Issuance Costs PaymentsOfPreferredStockIssuanceCosts	5500	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3320336	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1609989	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3014753	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4323478	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3137674	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5902199	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	122921	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1578721	usd
	ZVSA	Reclassification Of Formerly Redeemable Common Stock ReclassificationOfFormerlyRedeemableCommonStock	331331	usd
	ZVSA	Accounts Payable For Deferred Offering Costs AccountsPayableForDeferredOfferingCosts	176870	usd
	ZVSA	Accounts Payable For Deferred Offering Costs AccountsPayableForDeferredOfferingCosts	44892	usd
	ZVSA	Warrant Modification Incremental Value WarrantModificationIncrementalValue	181891	usd
	ZVSA	Warrant Inducement Offer Incremental Value WarrantInducementOfferIncrementalValue	246912	usd
	ZVSA	Warrant Inducement Offer Incremental Value WarrantInducementOfferIncrementalValue	134591	usd
CY2023Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Company effected a reverse stock split of its common stock at a ratio of 1-for-35 (the “2023 Reverse Split”). Upon the effectiveness of the 2023 Reverse Split, every 35 issued shares of common stock were reclassified and combined into one share of common stock.
CY2024Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Company effected a reverse stock split of its common stock at a ratio of 1-for-10 (the “2024 Reverse Split”). Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock. In addition,
CY2024Q3	us-gaap	Cash Cash	100000	usd
CY2024Q3	ZVSA	Working Capital Deficit WorkingCapitalDeficit	11200000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8000000.0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6300000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111200000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zdm4hdBmGwq6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_860_zMCpEm4hWs18">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	940371	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	116239	shares
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_848_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zCMJ0s5oTRX7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_864_z4jmfYZ3nO0e">Reclassifications</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period balances have been reclassified from security deposits to vendor deposits on the condensed consolidated balance sheet in order to conform to the current year presentation. These reclassifications had no effect on previously reported results of operations or loss per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	ZVSA	Milestone Payment Liability MilestonePaymentLiability	500000	usd
CY2024Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	979030	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	668803	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	163269	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	41969	usd
CY2024Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1107812	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	536500	usd
CY2024Q3	us-gaap	Other Liabilities OtherLiabilities	7261	usd
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	7261	usd
CY2024Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2257372	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1754533	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9707	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8859762	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0012	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0944	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0012	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0944	pure
CY2024Q2	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	992176	usd
CY2024Q3	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	162800	usd
CY2024Q3	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	76453	usd
CY2024Q3	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	81826	usd
CY2024Q3	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	87481	usd
CY2019Q1	us-gaap	Area Of Land AreaOfLand	3500
CY2019Q1	us-gaap	Lease Cost LeaseCost	89000	usd
CY2019Q1	us-gaap	Payments For Rent PaymentsForRent	497000	usd
CY2024Q3	ZVSA	Operating Lease Asset Amortization OperatingLeaseAssetAmortization	0	usd
	ZVSA	Operating Lease Asset Amortization OperatingLeaseAssetAmortization	7839	usd
CY2024Q3	us-gaap	Payments For Rent PaymentsForRent	42696	usd
	us-gaap	Payments For Rent PaymentsForRent	127439	usd
CY2023Q3	ZVSA	Operating Lease Asset Amortization OperatingLeaseAssetAmortization	38885	usd
	ZVSA	Operating Lease Asset Amortization OperatingLeaseAssetAmortization	116083	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	8656	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	74405	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y4M2D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065	pure
CY2024Q2	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	the Company effected the 2024 Reverse Split. Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock.
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	160665	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	243045	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	544902	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	896249	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	482559	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y3M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10243	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2218.51
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	604	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1760.50
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9639	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2247.21
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y6M
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6797	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2986.26
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M12D
CY2024Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	9639	shares
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P5Y8M12D
CY2024Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	6797	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	903320	shares
CY2023Q4	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	123.44
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	478600	shares
	ZVSA	Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice	3.46
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	227	shares
	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice	4053
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	453100	shares
	ZVSA	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercised In Period Weighted Average Exercised Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisedPrice	7.73
	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced Old ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedOld	-239300	shares
	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options In Period Weighted Average Exercise Price Repriced Old ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsInPeriodWeightedAverageExercisePriceRepricedOld	12.50
	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced New ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedNew	239300	shares
	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options In Period Weighted Average Exercise Price Repriced New ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsInPeriodWeightedAverageExercisePriceRepricedNew	3.46
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	928593	shares
CY2024Q3	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	114.83
	ZVSA	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerm2	P3Y8M23D
CY2024Q3	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	928393	shares
CY2024Q3	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	114.48
	ZVSA	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Non Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsNonOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y8M23D
CY2023Q1	ZVSA	Percentage Of Registration Delay Payments PercentageOfRegistrationDelayPayments	0.015	pure
CY2023Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.020	pure
	ZVSA	Accrued Registration Delay Payments AccruedRegistrationDelayPayments	7261	usd
	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
	ZVSA	Rule10b51 Arr Modified Flag Rule10b51ArrModifiedFlag	false
	ZVSA	Non Rule10b51 Arr Modified Flag NonRule10b51ArrModifiedFlag	false
	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-045351-index-headers.html	Edgar Link	pending
0001493152-24-045351-index.html	Edgar Link	pending
0001493152-24-045351.txt	Edgar Link	pending
0001493152-24-045351-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending
zvsa-20240930.xsd	Edgar Link	pending
zvsa-20240930_cal.xml	Edgar Link	unprocessable
zvsa-20240930_def.xml	Edgar Link	unprocessable
zvsa-20240930_pre.xml	Edgar Link	unprocessable
zvsa-20240930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZVSA
ZyVersa Therapeutics, Inc. Stock $zvsa

2024 Q4 Form 10-Q Financial Statement

#000149315224045351 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZVSA ZyVersa Therapeutics, Inc. Stock $zvsa

2024 Q4 Form 10-Q Financial Statement

#000149315224045351 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZVSA
ZyVersa Therapeutics, Inc. Stock $zvsa